Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT04389229 Withdrawn - Clinical trials for Ovarian Cancer Metastatic

OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)

OVSTAR
Start date: July 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

An open label, multi-centre Phase 1/2a study of modified and unmodified autologous Tumour Infiltrating Lymphocytes (TIL) in patients with platinum-resistant ovarian cancer. The purpose of this phase I/II study is to evaluate the feasibility and safety of both standard unmodified TIL (UTIL-01) and TIL engineered to express the co-stimulatory receptor CoStAR (CoTIL-01) in platinum resistant ovarian cancer.

NCT ID: NCT04383977 Not yet recruiting - Ovarian Cancer Clinical Trials

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

Start date: May 2020
Phase: Phase 2
Study type: Interventional

The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with apatinib (375 mg qd).

NCT ID: NCT04383210 Active, not recruiting - Breast Cancer Clinical Trials

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Start date: September 29, 2020
Phase: Phase 2
Study type: Interventional

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

NCT ID: NCT04377087 Terminated - Ovarian Cancer Clinical Trials

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Start date: June 29, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test if delaying the start of the olaparib until there is a rise in a tumor marker called CA-125 will result in a longer time until the next or different treatment for the patient's cancer. The study will also evaluate how delaying the start of maintenance therapy will affect symptoms; physical functioning; quality of life; and impact on finances.

NCT ID: NCT04375956 Recruiting - Ovarian Cancer Clinical Trials

Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients

MITO 27
Start date: April 26, 2021
Phase: Phase 2
Study type: Interventional

This is a single arm phase II, multicenter study evaluating Pembrolizumab in recurrent platinum resistant CPS score >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients.

NCT ID: NCT04368130 Withdrawn - Ovarian Cancer Clinical Trials

SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care

SIGNAL
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This research study is testing the use of a smartphone app to identify clinically meaningful changes in the behaviors of patients' with gynecological cancers by using passively collected smartphone data.

NCT ID: NCT04367467 Terminated - Breast Cancer Clinical Trials

Effect of PARP Inhibitors on Glomerular Filtration Rate

Start date: February 3, 2020
Phase:
Study type: Observational

The purpose of this study is to observe whether PARP inhibitors have an effect on serum creatinine level, and whether this reflects a change in creatinine secretion or a true change in kidney function.

NCT ID: NCT04354246 Recruiting - Lung Cancer Clinical Trials

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Start date: March 31, 2020
Phase: Phase 1
Study type: Interventional

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

NCT ID: NCT04352439 Completed - Ovarian Cancer Clinical Trials

Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy

Start date: August 8, 2020
Phase: Phase 4
Study type: Interventional

This is a pilot study to determine the safety and efficacy of low dose aspirin for the prevention of venous thromboembolism among women with advanced ovarian cancer receiving neoadjuvant chemotherapy.

NCT ID: NCT04339140 Recruiting - Ovarian Cancer Clinical Trials

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

Start date: June 24, 2020
Phase: Phase 2
Study type: Interventional

This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer. - The name of the study drug involved in this study is: - Zafirlukast